ArticleJournal of molecular histology2026
Integrative therapy with Qinghao Biejia Decoction improves survival after resection of intrahepatic cholangiocarcinoma.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Intrahepatic cholangiocarcinoma (ICC) is characterized by high postoperative recurrence and limited benefit from conventional adjuvant therapy. Qinghao Biejia Decoction (QHBJD), a classical traditional Chinese medicine formula, has demonstrated potential anticancer effects. This study investigated the molecular mechanisms of QHBJD in ICC and evaluated its impact on postoperative survival, with a focus on AKT1 expression. In this retrospective study of 60 patients with intrahepatic cholangiocarcinoma (ICC), network pharmacology and bioinformatics analyses were used to identify candidate targets of QHBJD. AKT1 expression was validated by immunohistochemistry in tissue microarrays, and associations between AKT1 expression, treatment strategies, and survival outcomes were assessed using Kaplan-Meier and Cox regression analyses. AKT1 was identified as a key target of QHBJD. In ICC tissues, AKT1 showed predominant nuclear localization, and high nuclear expression was associated with significantly shorter overall survival (OS) (18.4 vs. 25.1 months, p = 0.046). Postoperative adjuvant therapy alone did not significantly improve survival. In contrast, QHBJD-based integrative therapy significantly prolonged OS compared with no treatment (28.8 vs. 14.2 months, p = 0.041) and conventional therapy alone (28.8 vs. 11.2 months, p = 0.001). Among patients with high nuclear AKT1 expression, QHBJD significantly improved both disease-free survival (DFS) (5.95 vs. 2.0 months, p = 0.001) and OS (23.9 vs. 8.0 months, p < 0.001). Multivariate analysis confirmed QHBJD-based therapy as an independent protective factor for OS (HR 0.47, p < 0.05). QHBJD-based integrative therapy significantly improves survival in ICC, particularly in patients with high nuclear AKT1 expression, highlighting AKT1 as a potential therapeutic target and candidate prognostic biomarker that warrants further validation.
Indexed as
Identifiers
42878941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.